(161 days)
Not Found
No
The summary describes a physical medical device (a central venous catheter) and its intended use and performance testing. There is no mention of software, algorithms, or data processing that would indicate the presence of AI or ML.
No
The device is a central venous catheter used for administering fluids, blood products, and drugs, and for blood withdrawal. Its primary function is for access and delivery, not for treating a disease or condition itself.
No
The device is a central venous catheter for administering fluids and blood products, and blood withdrawal. It does not perform any diagnostic functions.
No
The device description clearly outlines physical components like a polyurethane catheter, Dacron cuff, and a subcutaneous port, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes a device for accessing the central venous system for administering substances and withdrawing blood. This is a direct interaction with the patient's body for therapeutic and diagnostic purposes (blood withdrawal), not for testing samples outside the body.
- Device Description: The description details a catheter and port designed for implantation and long-term access to the central venous system. This is consistent with an in-vivo medical device.
- Lack of IVD Characteristics: There is no mention of:
- Analyzing samples (blood, urine, tissue, etc.) in vitro.
- Detecting or measuring specific analytes.
- Providing information about a patient's health status based on laboratory testing.
- Reagents or assay components.
The device is a medical device used for direct patient care and intervention, not for performing diagnostic tests on samples.
N/A
Intended Use / Indications for Use
The NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter is indicated for long-term access to the Central Venous System. It is designed for administering IV fluids, blood products, drugs, and parenteral nutrition as well as blood withdrawal and power injection of contrast media. The maximum pressure of power injectors used with the NexSite device may not exceed 300psi.
Product codes (comma separated list FDA assigned to the subject device)
LJS
Device Description
The NexSite 9Fr Dual Lumen Catheter is a long-term central venous catheter. The polyurethane Catheter is 55.5cm in length, and has a Dacron cuff distal to the bifurcation hub. A Polyurethane/Dacron Port supplied with the Catheter is implanted subcutaneously, and is intended to minimize Catheter movement. The Catheter and Port are packaged with accessories that are used to facilitate Catheter and Port insertion.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Central Venous System
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
In vitro testing was performed on the NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter to assure reliable design and performance in accordance with ISO 10555-1 and ISO 10555-3. The non-clinical tests performed by the company include visual and dimensional, catheter leakage, catheter joint strength, catheter pressure, radiopacity, corrosion resistance, and catheter high pressure injection. The test results demonstrate that the NexSite Catheter meets the requirements in the applicable standards and specifications, and is substantially equivalent to legally marketed predicate devices.
In vivo testing was also performed to demonstrate that the device would perform as intended. Clinical studies were not deemed necessary since in vitro testing were sufficient to demonstrate safety and effectiveness by way of comparison to a legally marketed predicate device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5970 Percutaneous, implanted, long-term intravascular catheter.
(a)
Identification. A percutaneous, implanted, long-term intravascular catheter is a device that consists of a slender tube and any necessary connecting fittings, such as luer hubs, and accessories that facilitate the placement of the device. The device allows for repeated access to the vascular system for long-term use of 30 days or more, and it is intended for administration of fluids, medications, and nutrients; the sampling of blood; and monitoring blood pressure and temperature. The device may be constructed of metal, rubber, plastic, composite materials, or any combination of these materials and may be of single or multiple lumen design.(b)
Classification. Class II (special controls) Guidance Document: “Guidance on Premarket Notification [510(k)] Submission for Short-Term and Long-Term Intravascular Catheters.”
0
K 110627
2011
5. 510(k) Summary
General Information
March 3, 2011 Date Compiled
Class II. 21 CFR § 880.5970, Percutaneous, implanted, long-term Classification intravascular catheter, Product code LJS NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter Trade Name
Marvao Medical Devices, Ltd. Submitter GMIT Innovation in Business Centre, Dublin Road Galway, Ireland Marybeth Gamber Contact Boston Biomedical Associates Phone: (508) 351-8632
Fax: (508) 351-8637
Intended Use
The NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter is indicated for long-term access to the Central Venous System. It is designed for administering IV fluids, blood products, drugs, and parenteral nutrition as well as blood withdrawal and power injection of contrast media. The maximum pressure of power injectors used with the NexSite device may not exceed 300psi.
Predicate Devices
| PowerHickman® Central Venous Catheter
| Manufactured by Bard Access Systems | K061179 |
|---|---|
| Medcomp® PRO-LINE™ CT Power Injectable CVC | |
| Manufactured by Medcomp® | K053345 |
Device Description
The NexSite 9Fr Dual Lumen Catheter is a long-term central venous catheter. The polyurethane Catheter is 55.5cm in length, and has a Dacron cuff distal to the bifurcation hub. A Polyurethane/Dacron Port supplied with the Catheter is implanted subcutaneously, and is intended to minimize Catheter movement. The Catheter and Port are packaged with accessories that are used to facilitate Catheter and Port insertion.
Materials
The NexSite Catheter assembly is comprised of materials that are commonly used in medical device applications. Materials for the Catheter and Port include polyurethane, polycarbonate and Dacron.
1
Testing
In vitro testing was performed on the NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter to assure reliable design and performance in accordance with ISO 10555-1 and ISO 10555-3. The non-clinical tests performed by the company include visual and dimensional, catheter leakage, catheter joint strength, catheter pressure, radiopacity, corrosion resistance, and catheter high pressure injection. The test results demonstrate that the NexSite Catheter meets the requirements in the applicable standards and specifications, and is substantially equivalent to legally marketed predicate devices.
In vivo testing was also performed to demonstrate that the device would perform as intended. Clinical studies were not deemed necessary since in vitro testing were sufficient to demonstrate safety and effectiveness by way of comparison to a legally marketed predicate device.
Guidance
The FDA Guidance on Premarket Notification [(510(k)] Submission for Short-Term and Long-Term Intravascular Catheters, dated 3/16/95, was utilized in order to meet the FDA requirements for content and organization of this submission.
Summary of Substantial Equivalence
Marvao Medical believes the NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter is substantially equivalent to the predicate products. The intended use, method of operation, methods of construction and materials used, are either identical or substantially equivalent to existing legally marketed predicate products.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the bird symbol. The text is in all capital letters and is smaller than the bird symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room-WO66-G609 Silver Spring, MID 20993-0002
Marvao Medical Devices, Limited C/O Ms. Marybeth Gamber Principal Regulatory Consultant Boston Biomedical Associates 368 West Main Street, Suite 7 Northboro, Massachusetts 01532
AUG 1 2 2011
Re: K110627
Trade/Device Name: NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter Regulation Number: 21 CFR 880.5970 Regulation Name: Percutaneous, Implanted long-term Intravascular Catheter Regulatory Class: II Product Code: LJS Dated: July 14, 2011 Received: July 15, 2011
Dear Ms. Gamber:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2- Ms. Gamber
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820). and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ ucm 1 1 5809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Cintrony D. nut
Anthony D. Watson, B.S., M.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use Statement 4.
This application 510(k) Number (if known):
NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter Device Name:
The NexSite 9Fr Dual Lumen Critical Care Central Venous Catheter is indicated Indications for for long-term access to the Central Venous System. It is designed for Use: administering IV fluids, blood products, drugs, and parenteral nutrition as well as blood withdrawal and power injection of contrast media. The maximum pressure of power injectors used with the NexSite device may not exceed 300psi.
Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (Per 21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
Confidential
011
510(k) Number: K110627